Acetec

AceTec Biotherapeutics is a preclinical-stage biotechnology company focused on developing the next generation of conditionally activated bispecific antibodies for oncology. The company's proprietary Ace-body platform engineers T-cell engagers that remain inactive in systemic circulation and are selectively activated within the tumor microenvironment to minimize off-tumor toxicities. By leveraging this masking technology, AceTec aims to expand the therapeutic window of potent immunotherapies, particularly for solid tumors where traditional T-cell engagers have faced significant safety challenges. Headquartered in the San Francisco Bay Area, the company is led by experts in antibody engineering and immunotherapy.